Clinical Trial Results: Feasibility, Safety and Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Hospitalized Patients With AECOPD [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating nebulized long-acting bronchodilators versus short-acting bronchodilators in hospitalized COPD exacerbation patients; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• COPD Exacerbation
• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Albuterol (albuterol)
• Formoterol nebulized (formoterol)
• Ipratropium (ipratropium)
• Revefenacin nebulized (revefenacin)

Snippet

Sponsor: University of Tennessee Graduate School of Medicine | Conditions: COPD Exacerbation | Phase 4 | Status: COMPLETED | Results posted: 2026-08-03